Total psoriasis regression in a patient with chronic myeloid leukemia treated using nilotinib.

Chronic myeloid leukemia (CML) treatment has been revolutionized over last 20 years because of tyrosine kinase inhibitors (TKIs) and patients with CML now have life expectancy of general population. Chronic TKI treatment may cause adverse effects (AEs) that vary in frequency and severity. Nilotinib shows common AEs with metabolic changes and skin AEs. Here, we present a case report of patient who experienced full psoriasis regression while treated with nilotinib. Dose reductions and an attempt to stop nilotinib treatment resulted in prompt psoriasis reappearance. This is the first documented case of positive effect of nilotinib on psoriasis.
Competing Interests: Declarations. Ethics approval and consent to participate: The participant has consented to the submission of the case report to the journal. Competing interests: TH- Novartis (speakers bureau, consultancy), Angelini Pharma (consultancy), DZ- Novartis (speakers bureau, consultancy, member of advisory board), Angelini Pharma (speakers bureau, consultancy), JM- Novartis (research support), BMS (research support).
(© 2025. The Author(s).)